Dova Pharmaceuticals, which is commercializing an acquired drug candidate for low blood platelets, raised $75 million by offering 4.4 million shares at $17, the high end of the range of $15 to $17. Dova Pharmaceuticals plans to list on the Nasdaq under the symbol DOVA. J.P. Morgan, Jefferies and Leerink Partners acted as lead managers on the deal.
